Okami Medical
Aliso Viejo, US · Founded 2014 · Delaware corporation · 64 employees on LinkedIn · 3 known investors
Find your way into Okami Medical
Sign up to find every way you can get introduced to Okami Medical
- Your email: who you already know at Okami Medical, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Okami Medical team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters. Its products are intended for physicians treating peripheral vascular conditions.
Founders & leadership
Okami Medical was founded in 2014 by Brian J. Cox.
Board
Investors · 3
How we know: US Venture Partners's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: board seat on SEC Form D · funding news · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$77.2M disclosed across 8 rounds · 2016–2025
▶$28.9MraisedDec 2025 · 27 investors · Other TechnologyRule 506(b)
- Robert RosenbluthDirector
- Jonathan RootDirector
- Donald MilderDirector
- Mike KramerDirector
- William HoffmanDirector
- Andrew HykesExecutive Officer, Director
- Kirk NielsenDirector
- Paul LubockDirector
- Offering amount
- $46.7M
- Amount sold
- $28.9M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.6MraisedSep 2024 · 8 investors · Other TechnologyRule 506(b)
- Rhonda RobbExecutive Officer, Director
- Donald MilderDirector
- Robert RosenbluthDirector
- Paul LubockDirector
- Jonathan RootDirector
- Offering amount
- $30M
- Amount sold
- $18.6M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.7MraisedJan 2024 · 20 investors · Other TechnologyRule 506(b)
- Jonathan RootDirector
- Brian CoxDirector
- Paul LubockDirector
- Robert RosenbluthExecutive Officer, Director
- Donald MilderDirector
- Offering amount
- $6.1M
- Amount sold
- $5.7M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedSep 2021 · 19 investors · Other TechnologyRule 506(b)
- Brian CoxDirector
- Jonathan RootDirector
- Robert RosenbluthExecutive Officer, Director
- Paul LubockDirector
- Donald MilderDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedJun 2020 · 18 investors · Other TechnologyRule 506(b)
- Donald MilderDirector
- Jonathan RootDirector
- Robert RosenbluthExecutive Officer, Director
- Brian CoxDirector
- Paul LubockDirector
- Offering amount
- $7.2M
- Amount sold
- $7.2M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedApr 2019 · 18 investors · Other TechnologyRule 506(b)
- Jonathan RootDirector
- Donald MilderDirector
- Paul LubockDirector
- Brian CoxDirector
- Robert RosenbluthExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$4.5MraisedAug 2017 · 18 investors · BiotechnologyRule 506(b)
- Robert RosenbluthExecutive Officer
- Brian J. CoxExecutive Officer
- Paul LubockExecutive Officer
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- First sale
- Jun 2017
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$1.6MraisedMay 2016 · 14 investors · BiotechnologyRule 506(b)
- Brian J. CoxExecutive Officer
- Paul LubockExecutive Officer
- Robert RosenbluthExecutive Officer
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- May 2016
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Okami Medical.
In the news
Frequently asked questions
- What does Okami Medical do?
- Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters. Its products are intended for physicians treating peripheral vascular conditions.
- Who founded Okami Medical?
- Okami Medical was founded by Brian J. Cox in 2014.
- Who are Okami Medical's investors?
- Okami Medical's investors include US Venture Partners, Gilde Healthcare, Vensana Capital.
- How much funding has Okami Medical raised?
- Okami Medical has disclosed $77.2M raised across 8 rounds.
- Where is Okami Medical headquartered?
- Okami Medical is headquartered in Aliso Viejo, US.






